Sangamo Therapeutics (SGMOQ) Net Margin (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted Net Margin of 263.0% for Q4 2025, up 95.63% on a QoQ basis from 6012.05% in Q3 2025, and up 9694.0% year-over-year from 2.69% in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Net Margin (2010 - 2025) Analysis & Trends
Sangamo Therapeutics has reported Net Margin for 16 years, with the latest figure at 263.0% in Q4 2025.
- On a quarterly basis, Net Margin rose 9694.0% year-over-year to 263.0% in Q4 2025; TTM through Dec 2025 was 310.81%, a 13596.0% decrease from a year earlier, with the FY2025 full-year figure at 310.81%, down 14136.0% from the prior year.
- Net Margin was 263.0% for Q4 2025 at Sangamo Therapeutics, up from 6012.05% in the prior quarter.
- The five-year high for Net Margin was 18.99% in Q3 2024, with the low at 10205.61% in Q1 2024.
- Average Net Margin over 5 years is 1730.84%, with a median of 195.82% recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Net Margin tumbled 1021899 bps in 2024, then surged 1003914 bps in 2025.
- Over 5 years, Net Margin stood at 133.88% in 2021, then plunged by 42 bps to 190.76% in 2022, then tumbled by 1448 bps to 2952.74% in 2023, then surged by 88 bps to 359.94% in 2024, then advanced by 27 bps to 263.0% in 2025.
- The last three Net Margin figures came in at 263.0% (Q4 2025), 6012.05% (Q3 2025), and 109.18% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | 45.94% |
| 2 | CRISPR Therapeutics AG | 5.19 Bn | 5.19 Bn | - | -895.73% |
| 3 | Iovance Biotherapeutics | 3.76 Bn | 3.46 Bn | 55.72 Mn | -47.62% |
| 4 | Legend Biotech | 3.67 Bn | 2.71 Bn | 251.50 Mn | 20.08% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -1,387.76% |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | -25,036.33% |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.54 Bn | 251.87 Mn | -1.22% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 2.88% |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - | -263.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -263.00% |
| Sep 30, 2025 | -6,012.05% |
| Jun 30, 2025 | -109.18% |
| Mar 31, 2025 | -475.33% |
| Dec 31, 2024 | -359.94% |
| Sep 30, 2024 | 18.99% |
| Jun 30, 2024 | -10,148.31% |
| Mar 31, 2024 | -10,205.61% |
| Dec 31, 2023 | -2,952.74% |
| Sep 30, 2023 | -1,108.35% |
| Jun 30, 2023 | -1,675.29% |
| Mar 31, 2023 | 13.38% |
| Dec 31, 2022 | -190.76% |
| Sep 30, 2022 | -200.89% |
| Jun 30, 2022 | -146.96% |
| Mar 31, 2022 | -155.92% |
| Dec 31, 2021 | -133.88% |
| Sep 30, 2021 | -166.96% |
| Jun 30, 2021 | -169.23% |
| Mar 31, 2021 | -174.81% |